Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Prof John Allan - Weill Cornell Medicine, New York, USA

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )

Interim results of a phase II study of blinatumomab plus ponatinib for...

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia chromosome-positive ALL ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic...

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or...

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Real world evidence on the use of antibody drug conjugates in peripheral T-cell...

Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut...

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP...

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

Marizomib in combination with temozolomide-based radiochemotherapy for newly...

Dr Patrick Roth - University Hospital Zurich, Zurich, Switzerland

Marizomib in combination with temozolomide-based radiochemotherapy for newly diagnosed glioblastoma ( Dr Patrick Roth - University Hospital Zurich, Zurich, Switzerland )

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris...

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC ( Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, France )

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC

Dr Christina Baik - University of Washington School of Medicine, Seattle, USA

Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in...

Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

More from ecancer